autologous ROR2-targeted CAR-T cells CCT301-59

A preparation of genetically modified autologous T lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.